Hematocrit Levels and Hospitalization Risks in Hemodialysis Patients

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%.

Anemia treatment with epoetin has led to dramatic increases in hematocrit levels since 1989. Studies have demonstrated that morbidity and mortality rates are lower when hematocrit values are within the Disease Outcomes Quality Initiative (DOQI) target range (33 to 36%). Recently, clinical studies demonstrated that patients without cardiovascular disease exhibited lower morbidity rates and impro...

متن کامل

Hematocrit level and associated mortality in hemodialysis patients.

Although a number of clinical studies have shown that increased hematocrits are associated with improved outcomes in terms of cognitive function, reduced left ventricular hypertrophy, increased exercise tolerance, and improved quality of life, the optimal hematocrit level associated with survival has yet to be determined. The association between hematocrit levels and patient mortality was retro...

متن کامل

Infections Requiring Hospitalization in Patients on Hemodialysis.

Although the past decade has witnessed significant improvements in survival for patients receiving hemodialysis (HD) (1), hospitalization rates, particularly for infection, have not improved commensurately. Notable lack of progress is evident regarding hospitalizations for bacteremia/septicemia and pulmonary infections, such as pneumonia and influenza (2). For bacteremia/septicemia, first–year ...

متن کامل

Weekly subcutaneous erythropoietin maintains hematocrit in chronic hemodialysis patients.

R ecombinant human enythropoietin (r-HuEPO) is widely used to treat the anemia of chronic renal failure. Standard therapy is to administer r-HuEPO at doses of 50 to 1 50 U/kg iv three times a week after hemodiabysis treatment (1-3). This route of administration and dosing schedule are based on pharmacokmnetic studies that demonstrate that the half-life for an iv dose is approximately 6 to 9 h (...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of the American Society of Nephrology

سال: 1999

ISSN: 1046-6673,1533-3450

DOI: 10.1681/asn.v1061309